{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:02:05Z","timestamp":1761102125674,"version":"build-2065373602"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.hoc.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,10,5]],"date-time":"2014-10-05T16:49:13Z","timestamp":1412527753000},"page":"1037-1053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chronic Myeloid Leukemia\u2013Transplantation in the Tyrosine Kinase Era"],"prefix":"10.1016","volume":"28","author":[{"given":"Andrew J.","family":"Innes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane F.","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2014.08.002_bib1","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.seminhematol.2010.07.001","article-title":"Chronic myeloid leukemia: a historical perspective","volume":"47","author":"Goldman","year":"2010","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM197902153000702","article-title":"Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin","volume":"300","author":"Fefer","year":"1979","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.002_bib3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal break points are clustered within a limited region, bcr. on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2014.08.002_bib4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"122","key":"10.1016\/j.hoc.2014.08.002_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib6","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib7","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.002_bib8","doi-asserted-by":"crossref","unstructured":"Deininger M, O'Brien SG, Guilhot F. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. 2009 114: Abstract 1126.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"10.1016\/j.hoc.2014.08.002_bib9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib10","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib11","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.002_bib12","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","article-title":"Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia","volume":"53","author":"Steegmann","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2014.08.002_bib13","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.002_bib14","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib15","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2011.09.005","article-title":"BCR-ABL mutations in chronic myeloid leukemia","volume":"25","author":"Ernst","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2014.08.002_bib16","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2013-10-532341","article-title":"Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study","volume":"123","author":"Shah","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib18","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12187","article-title":"BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib","volume":"160","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.002_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s001090050173","article-title":"Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia","volume":"75","author":"Griesshammer","year":"1997","journal-title":"J\u00a0Mol Med"},{"key":"10.1016\/j.hoc.2014.08.002_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib22","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia","volume":"22","author":"Silver","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3324\/haematol.2011.057513","article-title":"Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation","volume":"97","author":"Milojkovic","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.002_bib25","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2014.08.002_bib27","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2014.08.002_bib29","first-page":"S34","article-title":"Prognostic significance of EBMT score for chronic myeloid leukaemia patients in the era of tyrosine kinase inhibitor therapy: a retrospective study from the chronic malignancy working party of the European Group For Blood and Marrow Transplantation (EBMT)","volume":"49","author":"Milojkovic","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2011.06.010","article-title":"EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure","volume":"18","author":"Rezvani","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib32","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib33","doi-asserted-by":"crossref","first-page":"4606","DOI":"10.1182\/blood-2007-06-096966","article-title":"Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences","volume":"110","author":"Sorror","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib34","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/cncr.23375","article-title":"Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation","volume":"112","author":"Sorror","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.002_bib35","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2008.002063","article-title":"The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome","volume":"94","author":"Zipperer","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.002_bib36","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavl\u016f","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: what have we learned?","volume":"117","author":"Pavl\u016f","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib38","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.002_bib39","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib40","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/leu.2008.401","article-title":"Reduced-intensity allogeneic transplantation combined with imatinib mesylate for chronic myeloid leukemia in first chronic phase","volume":"23","author":"Luo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib42","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00277-010-1081-3","article-title":"Long-term outcomes of HLA-matched sibling compared with mismatched related and unrelated donor hematopoietic stem cell transplantation for chronic phase chronic myelogenous leukemia: a single institution experience in China","volume":"90","author":"Liu","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib43","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis","volume":"47","author":"Khoury","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib44","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.bbmt.2013.09.008","article-title":"Comparison of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in advanced stage","volume":"19","author":"Zheng","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2008.160","volume":"23","author":"Shimoni","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.002_bib46","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.bbmt.2009.03.013","article-title":"Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia","volume":"15","author":"Copelan","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib47","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00277-009-0737-3","article-title":"The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia\u2014a report from the German Registry covering the period from 1998 to 2004","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib48","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.bbmt.2010.05.014","article-title":"Single-unit umbilical cord blood transplantation from unrelated donors in adult patients with chronic myelogenous leukemia","volume":"16","author":"Sanz","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib49","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib50","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00277-011-1349-2","article-title":"Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients","volume":"91","author":"Topcuoglu","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/ajh.23263","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up","volume":"87","author":"Zuckerman","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2014.08.002_bib53","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/blood-2012-02-409763","article-title":"Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era","volume":"119","author":"Warlick","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib54","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.002_bib55","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib56","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2002-02-0571","article-title":"Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation","volume":"101","author":"Uzunel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib57","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplant","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V118.21.4103.4103","article-title":"The majority of patients receiving donor lymphocyte infusions for relapsed chronic myeloid leukemia remain PCR positive despite maintaining long-term remission","volume":"118","author":"Innes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib59","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/bmt.2013.69","article-title":"Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT","volume":"48","author":"Innes","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.002_bib60","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1182\/blood.V86.4.1261.bloodjournal8641261","article-title":"Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease","volume":"86","author":"Mackinnon","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib61","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1182\/blood.V95.1.67","article-title":"Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia","volume":"95","author":"Dazzi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.002_bib62","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1038\/sj.leu.2403068","article-title":"Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"17","author":"Olavarria","year":"2003","journal-title":"Leukemia"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:13Z","timestamp":1760184073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0889858814001026"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.002","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myeloid Leukemia\u2013Transplantation in the Tyrosine Kinase Era","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}